Stockscreener 앱 받기
1.63
2.52%
0.04
시간 외 거래:
1.65
0.02
+1.23%
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration - simplywall.st
Lineage Announces Formation of Scientific Advisory Board - BioSpace
Lineage Cell Therapeutics (LCTX) Establishes New Scientific Advi - GuruFocus
Lineage Cell Therapeutics forms advisory board, names clinical head By Investing.com - Investing.com Australia
Lineage Cell Therapeutics forms advisory board, names clinical head - Investing.com
Guidance Update: Can Lineage Cell Therapeutics Inc maintain sales growth2026 Market Trends & Reliable Intraday Trade Alerts - baoquankhu1.vn
Tech Rally: Is Lineage Cell Therapeutics Inc still a buy after recent gains2026 Stock Rankings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
If You Invested $1,000 in Lineage Cell The (LCTX) - Stock Titan
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - PR Newswire
Biotechs Racing to Translate Longevity Science Into Real TherapiesAnd One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - The Malaysian Reserve
Lineage Cell Therapeutics launches COR1 for corneal diseases amid rising FECD prevalence - Traders Union
Q4 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Pharma News: Can Lineage Cell Therapeutics Inc reach resistance levels soon2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines - Sahm
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
Lineage Cell Therapeutics (LCTX) price target increased by 20.00% to 5.10 - MSN
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Lineage Cell Therapeutics pushes scalable platforms to address drug discovery complexity - Traders Union
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance UK
Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program - Yahoo Finance
Earnings Miss: What are the future prospects of Lineage Cell Therapeutics Inc2026 Trade Ideas & Long-Term Growth Stock Strategies - baoquankhu1.vn
Lineage Cell Therapeutics launches new CED cell therapy program - Eyes On Eyecare
10 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Volume Recap: Can Lineage Cell Therapeutics Inc maintain sales growthTrade Performance Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Retail Trends: Is now the right time to enter Lineage Cell Therapeutics IncGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Aug Breakouts: Is Lineage Cell Therapeutics Inc stock overvalued or fairly priced2026 Institutional Moves & Safe Entry Momentum Stock Tips - baoquankhu1.vn
LCTX Should I Buy - Intellectia AI
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
B. Riley Financial Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - MarketBeat
ETF Watch: Is Lineage Cell Therapeutics Inc a top pick in the sector2026 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
LCTX: HC Wainwright Reiterates Buy Rating with $9 Price Target | - GuruFocus
HC Wainwright Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease - BioSpace
Lineage Cell Therapeutics unveils preclinical therapy for Fuchs dystrophy and Bullous Keratopathy - Traders Union
Lineage Cell Therapeutics (LCTX) Expands with New Corneal Cell T - GuruFocus
[EFFECT] Lineage Cell Therapeutics, Inc. SEC Filing - Stock Titan
Geopolitics Watch: Can Lineage Cell Therapeutics Inc scale operations efficiently2026 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Insider Buying: Brian Culley Acquires 15,000 Shares of Lineage C - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Brian Culley Purchases 15,000 Shares - MarketBeat
Lineage Cell Therapeutics (LCTX) CEO adds 15,000 shares in open-market purchase - Stock Titan
Lineage Therap Expands ATM Equity Offering Capacity - The Globe and Mail
Lineage Cell Therapeutics, Inc. Files Form 8-K for At-The-Market Offering – Key Company and Security Information (LCTX, NYSEAMER) 232425 - Minichart
Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs - MSN
Lineage Cell Therapeutics files prospectus supplement for up to $60 million share offering - Investing.com
Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM equity offering - TradingView
2.69%
0.25%
자본화:
|
볼륨(24시간):